- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04358198
AI in GIM Diagnosis
March 28, 2022 updated by: Rapat Pittayanon, King Chulalongkorn Memorial Hospital
Usefulness of Artificial Intelligence (AI) for Gastric Intestinal Metaplasia Diagnosis
This study will use artificial intelligence (AI) for diagnosing gastric intestinal metaplasia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The patients with previously diagnose gastric intestinal metaplasia (GIM) and have the surveillance gastroscopy will be enrolled.
The routine surveillance program will be performed additional to taking photo at both GIM and normal mucosa at least 5 pictures in each.
Biopsy will be done to confirm the diagnosis of GIM and normal mucosa.
All pictures will be inserted to AI algorithm based on the convolutional neural network (CNN).
Then, the AI program will be validated in daily endoscopy compared with pathology.
Accuracy, sensitivity and specificity can be calculated by 2x2 table.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rapat Pittayanon, MD
- Phone Number: 66804224999
- Email: rapat125@gmail.com
Study Locations
-
-
Bangkok
-
Pathum Wan, Bangkok, Thailand, 10330
- Recruiting
- Rapat Pittayanon
-
Contact:
- Rapat Pittayanon
- Email: rapat125@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- More than 18 years of age
- Able to sign a consent form
Exclusion Criteria:
- History of gastric surgery
- Coagulopathy
- Pregnancy/Breast feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: GIM patient
The patients with GIM will be assessed at both GIM and normal mucosa during endoscopy.
|
The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa.
Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of AI for GIM diagnosis
Time Frame: 1 year
|
Accuracy, sensitivity, specificity can be calculated by 2x2 table (pathology is a gold standard)
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2020
Primary Completion (Anticipated)
November 30, 2023
Study Completion (Anticipated)
February 28, 2024
Study Registration Dates
First Submitted
April 12, 2020
First Submitted That Met QC Criteria
April 21, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
March 31, 2022
Last Update Submitted That Met QC Criteria
March 28, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GIM Diagnosis
-
University Health Network, TorontoActive, not recruitingGIM Diagnosis | Medicine | Admission to GIMCanada
-
St. Mary's Research Center, CanadaCompletedLength of Stay | Emergency Geriatric Care | Geriatric Health | Admission to GIMCanada
-
Umraniye Education and Research HospitalCompleted
-
SuperSonic ImagineTerminated
-
Peking Union Medical College HospitalNot yet recruitingPrenatal Diagnosis
-
Danderyd HospitalRecruiting
-
European Institute of OncologyEuropean UnionRecruitingCancer DiagnosisFrance, Lithuania, Germany, Italy, Spain
-
Vrije Universiteit BrusselRecruitingPerinatal Palliative Care | Life-limiting Fetal Diagnosis | Life-limiting Neonatal DiagnosisBelgium
-
University of AlbertaCompleted
-
Ankara Education and Research HospitalCompletedDiagnosis | Axilla; BreastTurkey
Clinical Trials on Artificial intelligence
-
Fujian Provincial HospitalRecruitingEarly Esophageal Cancer | Esophageal Cancer StageChina
-
Brigham and Women's HospitalActive, not recruitingProstate CancerUnited States
-
Sheba Medical CenterCompleted
-
Docbot, Inc.RecruitingColorectal Adenoma | Colorectal Adenocarcinoma | Colorectal Polyp | Colorectal SSAUnited States
-
The First Hospital of Jilin UniversityRecruiting
-
The First Hospital of Jilin UniversityRecruiting
-
China-Japan Friendship HospitalRecruitingPulmonary Embolism | Chronic Thromboembolic Pulmonary Hypertension | Chronic Thromboembolic Pulmonary DiseaseChina
-
University of Wisconsin, MadisonCompleted
-
Istituto Clinico HumanitasCompletedArtificial IntelligenceItaly
-
Istituto Clinico HumanitasCompletedArtificial IntelligenceItaly